Stocklytics Platform
Asset logo for symbol HAE
Haemonetics
HAE65
$60.34arrow_drop_up2.01%$1.19
Asset logo for symbol HAE
HAE65

$60.34

arrow_drop_up2.01%
Key Stats
Open$60.47
Prev. Close$59.15
EPS2.54
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range59.15
62.30
52 Week Range55.44
97.97
Ratios
EPS2.54
Fundamentals
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

HAE-
US Healthcare Sector-
US Market-
check_circle

HAE / Market

HAE exceeded the US Market which returned 1.35% over the last twenty four hours.
warning

HAE / Healthcare Sector

HAE lose to the US Healthcare sector which returned 3.60% over the last twenty four hours.

Haemonetics (HAE) Statistics

Haemonetics Corp (HAE) is a leading global provider of blood management solutions, serving customers across the healthcare continuum. The company specializes in developing innovative products and services that help healthcare providers improve patient outcomes, increase operational efficiency, and reduce costs. With a strong focus on research and development, Haemonetics Corp is committed to advancing the field of blood management through technology and data-driven solutions.
When it comes to valuation metrics, Haemonetics Corp exhibits strong performance. The company has a price-to-earnings ratio of 37.85, indicating that investors are willing to pay a premium for its shares. Additionally, Haemonetics Corp has a price-to-sales ratio of 4.59, demonstrating its solid revenue generation. These metrics suggest that the market recognizes the company's growth potential and is optimistic about its future prospects.
add Haemonetics to watchlist

Keep an eye on Haemonetics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Haemonetics (HAE) stock's performance compared to its sector and the market over the past year?

Over the past year, Haemonetics (HAE) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 22.20%, Haemonetics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 37.38%, it has fallen short of the market average. This comparison highlights Haemonetics's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Haemonetics (HAE) stock?

The PE (Price to Earnings) ratio of Haemonetics (HAE) is currently 23.76. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of Haemonetics (HAE) stock?

The Earnings Per Share (EPS) for Haemonetics (HAE), calculated on a diluted basis, is $2.54. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Haemonetics (HAE) stock?

The operating margin for Haemonetics (HAE) is 18.97%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Haemonetics (HAE) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Haemonetics (HAE) is $293.44M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Haemonetics (HAE) have?

Haemonetics (HAE) has a total debt of $1.29B. The net debt, which accounts for cash and cash equivalents against the total debt, is $903.99M.

Take Your Investments to a Whole New Level